Premium
Unusual serological findings associated with ceftriaxone‐induced immune hemolytic anemia in a child with disseminated low‐grade glioma
Author(s) -
Pecker L. H.,
Timsar A.,
Pary P. P.,
Denomme G. A.,
Criss V. R.,
Luban N. L. C.,
Hwang E. I.,
Wong E. C. C.
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26101
Subject(s) - medicine , ceftriaxone , serology , blood cancer , hemolytic anemia , immune system , glioma , immunology , antibody , antibiotics , microbiology and biotechnology , cancer , cancer research , biology
Abstract Ceftriaxone‐induced immune hemolytic anemia (CIHA) is the second most common cause of drug‐induced hemolytic anemia. Prompt recognition of this drug reaction is essential because brisk hemolysis can be deadly. The extent to which ceftriaxone antibodies persist after CIHA is unknown; rechallenging patients who have experienced CIHA is not recommended. We report a case of CIHA in a neurooncology patient, which is the first to show anticeftriaxone antibodies with Rh specificity and persisted for 8 months after the drug reaction. These findings have implications for understanding the mechanism of CIHA.